117 related articles for article (PubMed ID: 12852343)
21. Successful long-term control with lamivudine against reactivated hepatitis B infection following intensive chemotherapy and autologous peripheral blood stem cell transplantation in non-Hodgkin's lymphoma: experience of 2 cases.
Nakagawa M; Simizu Y; Suemura M; Sato B
Am J Hematol; 2002 May; 70(1):60-3. PubMed ID: 11994984
[TBL] [Abstract][Full Text] [Related]
22. Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core-antibody-positive donors.
Prakoso E; Strasser SI; Koorey DJ; Verran D; McCaughan GW
Clin Transplant; 2006; 20(3):369-73. PubMed ID: 16824156
[TBL] [Abstract][Full Text] [Related]
23. Effect of long-term lamivudine in chronic hepatitis B virus-infected children.
Ozgenç F; Arikan C; Sertoz RY; Nart D; Aydogdu S; Yagci RV
Antivir Ther; 2004 Oct; 9(5):729-32. PubMed ID: 15535410
[TBL] [Abstract][Full Text] [Related]
24. [New developments in therapy of chronic hepatitis B. When are nucleoside analogs indicated?].
Petry W; Erhardt A; Heintges T; Häussinger D
Z Gastroenterol; 2000 Jan; 38(1):77-87. PubMed ID: 10689749
[TBL] [Abstract][Full Text] [Related]
25. [Effect of lamivudine for hepatitis B virus reactivation in blood cancer patients undergoing immunosuppressive chemotherapy].
Sugimoto R; Enjoji M; Kotoh K; Noguchi K; Tsuruta S; Nakamuta M; Nawata H
Fukuoka Igaku Zasshi; 2004 Oct; 95(10):274-9. PubMed ID: 15678886
[TBL] [Abstract][Full Text] [Related]
26. Hepatitis B virus reactivation in patients receiving chemotherapy for cancer treatment: role of Lamivudine prophylaxis.
Coiffier B
Cancer Invest; 2006; 24(5):548-52. PubMed ID: 16939967
[TBL] [Abstract][Full Text] [Related]
27. Long-term experience with lamivudine therapy for hepatitis B virus infection after liver transplantation.
Ben-Ari Z; Mor E; Shapira Z; Tur-Kaspa R
Liver Transpl; 2001 Feb; 7(2):113-7. PubMed ID: 11172394
[TBL] [Abstract][Full Text] [Related]
28. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial.
Hsu C; Hsiung CA; Su IJ; Hwang WS; Wang MC; Lin SF; Lin TH; Hsiao HH; Young JH; Chang MC; Liao YM; Li CC; Wu HB; Tien HF; Chao TY; Liu TW; Cheng AL; Chen PJ
Hepatology; 2008 Mar; 47(3):844-53. PubMed ID: 18302293
[TBL] [Abstract][Full Text] [Related]
29. Hepatitis B virus reactivation after fludarabine-based regimens for indolent non-Hodgkin's lymphomas: high prevalence of acquired viral genomic mutations.
Picardi M; Pane F; Quintarelli C; De Renzo A; Del Giudice A; De Divitiis B; Persico M; Ciancia R; Salvatore F; Rotoli B
Haematologica; 2003 Nov; 88(11):1296-303. PubMed ID: 14607759
[TBL] [Abstract][Full Text] [Related]
30. Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma.
Tsutsumi Y; Tanaka J; Kawamura T; Miura T; Kanamori H; Obara S; Asaka M; Imamura M; Masauzi N
Ann Hematol; 2004 Jan; 83(1):58-60. PubMed ID: 14513286
[TBL] [Abstract][Full Text] [Related]
31. Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: precore/core mutations may play an important role.
Steinberg JL; Yeo W; Zhong S; Chan JY; Tam JS; Chan PK; Leung NW; Johnson PJ
J Med Virol; 2000 Mar; 60(3):249-55. PubMed ID: 10630955
[TBL] [Abstract][Full Text] [Related]
32. Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation.
Giaccone L; Festuccia M; Marengo A; Resta I; Sorasio R; Pittaluga F; Fiore F; Boccadoro M; Rizzetto M; Bruno B; Marzano A
Biol Blood Marrow Transplant; 2010 Jun; 16(6):809-17. PubMed ID: 20060484
[TBL] [Abstract][Full Text] [Related]
33. Lamivudine prophylaxis in HBV carriers with haemato-oncological malignancies who receive chemotherapy.
Idilman R
J Antimicrob Chemother; 2005 Jun; 55(6):828-31. PubMed ID: 15849263
[TBL] [Abstract][Full Text] [Related]
34. Prevalence of hepatitis B and C virus infection in haematological malignancies and liver injury following chemotherapy.
Takai S; Tsurumi H; Ando K; Kasahara S; Sawada M; Yamada T; Hara T; Fukuno K; Takahashi T; Oyama M; Onishi H; Tomita E; Takami T; Imawari M; Moriwaki H
Eur J Haematol; 2005 Feb; 74(2):158-65. PubMed ID: 15654908
[TBL] [Abstract][Full Text] [Related]
35. Lamivudine for chemotherapy-induced reactivation of HBV: prophylaxis or treatment?
Mancuso A; Pagliaro L
Am J Gastroenterol; 2002 May; 97(5):1268-9. PubMed ID: 12014746
[No Abstract] [Full Text] [Related]
36. Severe liver disease is caused by HBV rather than HCV in children with hematological malignancies.
El-Sayed MH; Mohamed MM; Karim A; Maina AM; Oliveri F; Brunetto MR; Bonino F
Hematol J; 2003; 4(5):321-7. PubMed ID: 14502256
[TBL] [Abstract][Full Text] [Related]
37. Extended lamivudine therapy against hepatitis B virus infection in hematopoietic stem cell transplant recipients.
Hsiao LT; Chiou TJ; Liu JH; Chu CJ; Lin YC; Chao TC; Wang WS; Yen CC; Yang MH; Tzeng CH; Chen PM
Biol Blood Marrow Transplant; 2006 Jan; 12(1):84-94. PubMed ID: 16399572
[TBL] [Abstract][Full Text] [Related]
38. A single-center, prospective and randomized controlled study: Can the prophylactic use of lamivudine prevent hepatitis B virus reactivation in hepatitis B s-antigen seropositive breast cancer patients during chemotherapy?
Long M; Jia W; Li S; Jin L; Wu J; Rao N; Feng H; Chen K; Deng H; Liu F; Su F; Song E
Breast Cancer Res Treat; 2011 Jun; 127(3):705-12. PubMed ID: 21445574
[TBL] [Abstract][Full Text] [Related]
39. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy.
Chayama K; Suzuki Y; Kobayashi M; Kobayashi M; Tsubota A; Hashimoto M; Miyano Y; Koike H; Kobayashi M; Koida I; Arase Y; Saitoh S; Murashima N; Ikeda K; Kumada H
Hepatology; 1998 Jun; 27(6):1711-6. PubMed ID: 9620347
[TBL] [Abstract][Full Text] [Related]
40. Prevention of hepatitis B flare-up during chemotherapy using lamivudine: case report and review of the literature.
Al-Taie OH; Mörk H; Gassel AM; Wilhelm M; Weissbrich B; Scheurlen M
Ann Hematol; 1999 May; 78(5):247-9. PubMed ID: 10391107
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
